NasdaqGM:OCULPharmaceuticals
Assessing Ocular Therapeutix (OCUL) Valuation As AXPAXLI Prospects Drive A Wide Gap To Fair Value Estimates
Ocular Therapeutix (OCUL) has caught investor attention after recent share price swings, with the stock closing at US$9.32. The company focuses on bioresorbable hydrogel therapies for retinal diseases and other eye conditions.
See our latest analysis for Ocular Therapeutix.
Recent trading has been choppy, with a 1 day share price return of 2.1% decline, a 7 day gain of 6.39%, and a 30 day share price return of 13.94%. Even so, the 90 day share price return of 18.39% decline and year to date...